Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits

Retrovirology

Volumn 11, Issue 1, 2014, Pages

  Yasmeen, Anila ^a   Ringe, Rajesh ^a   Derking, Ronald ^b   Cupo, Albert ^a   Julien, Jean Philippe ^c   Burton, Dennis R ^d,e   Ward, Andrew B ^c   Wilson, Ian A ^c,d   Sanders, Rogier W ^a,b   Moore, John P ^a   Klasse, Per J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; CD4 ANTIGEN; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PROTEIN BINDING; PROTEIN SUBUNIT;

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BINDING SITE; CONTROLLED STUDY; DISULFIDE BOND; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; NONHUMAN; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN QUATERNARY STRUCTURE; STOICHIOMETRY; SURFACE PLASMON RESONANCE; VIRION; VIRUS ISOLATION; VIRUS MUTATION; VIRUS NEUTRALIZATION; CELL LINE; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; METABOLISM; PROTEIN MULTIMERIZATION; PROTEIN SUBUNIT;

ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; CELL LINE; EPITOPES; HEK293 CELLS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN SUBUNITS;

EID: 84903173697     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-11-41     Document Type: Article

References (93)

1. Checkley MA, Luttge BG, Freed EO. HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol 2011, 410:582-608. 10.1016/j.jmb.2011.04.042, 3139147, 21762802.
2. Klasse PJ. The molecular basis of HIV entry. Cell Microbiol 2012, 14:1183-1192. 10.1111/j.1462-5822.2012.01812.x, 3417324, 22583677.
3. Melikyan GB. Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm. Retrovirology 2008, 5:111. doi:10.1186/1742-4690-5-111, 10.1186/1742-4690-5-111, 2633019, 19077194.
4. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, Scanlan CN, Schief WR, Silvestri G, Streeck H, Walker BD, Walker LM, Ward AB, Wilson IA, Wyatt R. A Blueprint for HIV Vaccine Discovery. Cell Host Microbe 2012, 12:396-407. 10.1016/j.chom.2012.09.008, 3513329, 23084910.
5. Phogat S, Wyatt R. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr Pharm Des 2007, 13:213-227. 10.2174/138161207779313632, 17269929.
6. Klasse PJ, Sanders RW, Cerutti A, Moore JP. How can HIV-Type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?. AIDS Res Hum Retroviruses 2012, 28:1-15. 10.1089/aid.2011.0053, 3251839, 21495876.
7. Binley JM, Sanders RW, Clas B, Schuelke N, Master A, Guo Y, Kajumo F, Anselma DJ, Maddon PJ, Olson WC, Moore JP. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 2000, 74:627-643. 10.1128/JVI.74.2.627-643.2000, 111582, 10623724.
8. Binley JM, Sanders RW, Master A, Cayanan CS, Wiley CL, Schiffner L, Travis B, Kuhmann S, Burton DR, Hu SL, Olson WC, Moore JP. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 2002, 76:2606-2616. 10.1128/JVI.76.6.2606-2616.2002, 135977, 11861826.
9. Earl PL, Broder CC, Long D, Lee SA, Peterson J, Chakrabarti S, Doms RW, Moss B. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 1994, 68:3015-3026. 236792, 7512157.
10. Gao F, Weaver EA, Lu Z, Li Y, Liao HX, Ma B, Alam SM, Scearce RM, Sutherland LL, Yu JS, Decker JM, Shaw GM, Montefiori DC, Korber BT, Hahn BH, Haynes BF. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 2005, 79:1154-1163. 10.1128/JVI.79.2.1154-1163.2005, 538535, 15613343.
11. Klasse PJ, Depetris RS, Pejchal R, Julien JP, Khayat R, Lee JH, Marozsan AJ, Cupo A, Cocco N, Korzun J, Yasmeen A, Ward AB, Wilson IA, Sanders RW, Moore JP. Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. J Virol 2013, 87:9873-9885. 10.1128/JVI.01226-13, 3754145, 23824824.
12. Kovacs JM, Nkolola JP, Peng H, Cheung A, Perry J, Miller CA, Seaman MS, Barouch DH, Chen B. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci U S A 2012, 109:12111-12116. 10.1073/pnas.1204533109, 3409750, 22773820.
13. Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, Kalyanaraman R, Paluch M, Berkhout B, Maddon PJ, Olson WC, Lu M, Moore JP. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2002, 76:8875-8889. 10.1128/JVI.76.17.8875-8889.2002, 136973, 12163607.
14. Spearman P, Lally MA, Elizaga M, Montefiori D, Tomaras GD, McElrath MJ, Hural J, De Rosa SC, Sato A, Huang Y, Frey SE, Sato P, Donnelly J, Barnett S, Corey LJ. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis 2011, 203:1165-1173. 10.1093/infdis/jiq175, 3068023, 21451004.
15. Yang X, Lee J, Mahony EM, Kwong PD, Wyatt R, Sodroski J. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 2002, 76:4634-4642. 10.1128/JVI.76.9.4634-4642.2002, 155086, 11932429.
16. Julien JP, Lee JH, Cupo A, Murin CD, Derking R, Hoffenberg S, Caulfield MJ, King CR, Marozsan AJ, Klasse PJ, Sanders RW, Moore JP, Wilson IA, Ward AB. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A 2013, 110:4351-4356. 10.1073/pnas.1217537110, 3600498, 23426631.
17. Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, De Val N, Kim HJ, Blattner C, de la Pena AT, Korzun J, Golabek M, De Los Reyes K, Ketas TJ, Van Gils MJ, King CR, Wilson IA, Ward AB, Klasse PJ, Moore JP. A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 2013, 9:e1003618. 10.1371/journal.ppat.1003618, 3777863, 24068931.
18. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1477-1483. 10.1126/science.1245625, 24179159.
19. Lyumkis D, Julien JP, De Val N, Cupo A, Potter CS, Klasse PJ, Burton DR, Sanders RW, Moore JP, Carragher B, Wilson IA, Ward AB. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1484-1490. 10.1126/science.1245627, 24179160.
20. Sanders RW, Schiffner L, Master A, Kajumo F, Guo Y, Dragic T, Moore JP, Binley JM. Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits. J Virol 2000, 74:5091-5100. 10.1128/JVI.74.11.5091-5100.2000, 110861, 10799583.
21. Pancera M, Lebowitz J, Schon A, Zhu P, Freire E, Kwong PD, Roux KH, Sodroski J, Wyatt R. Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: Characterization and ligand binding analysis. J Virol 2005, 79:9954-9969. 10.1128/JVI.79.15.9954-9969.2005, 1181572, 16014956.
22. Guttman M, Lee KK. A functional interaction between gp41 and gp120 is observed for monomeric but not oligomeric, uncleaved HIV-1 Env gp140. J Virol 2013, 87:11462-11475. 10.1128/JVI.01681-13, 3807357, 23966389.
23. Ringe RP, Sanders RW, Yasmeen A, Kim HJ, Lee JH, Cupo A, Korzun J, Derking R, Van Montfort T, Julien JP, Wilson IA, Klasse PJ, Ward AB, Moore JP. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A 2013, 110:18256-18261. 10.1073/pnas.1314351110, 3831437, 24145402.
24. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat Med 2009, 15:866-870.
25. Parren PW, Burton DR, Sattentau QJ. HIV-1 antibody-debris or virion?. Nat Med 1997, 3:366-367.
26. Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, Grise H, Corcoran P, Zwick MB, Franti M, Morris L, Roux KH, Burton DR, Binley JM. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 2006, 80:2515-2528. 10.1128/JVI.80.5.2515-2528.2006, 1395414, 16474158.
27. Poignard P, Moulard M, Golez E, Vivona V, Franti M, Venturini S, Wang M, Parren PW, Burton DR. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol 2003, 77:353-365. 10.1128/JVI.77.1.353-365.2003, 140593, 12477840.
28. Fouts TR, Binley JM, Trkola A, Robinson JE, Moore JP. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J Virol 1997, 71:2779-2785. 191401, 9060632.
29. Parren PW, Mondor I, Naniche D, Ditzel HJ, Klasse PJ, Burton DR, Sattentau QJ. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol 1998, 72:3512-3519. 109569, 9557629.
30. Kwon YD, Finzi A, Wu X, Dogo-Isonagie C, Lee LK, Moore LR, Schmidt SD, Stuckey J, Yang Y, Zhou T, Zhu J, Vicic DA, Debnath AK, Shapiro L, Bewley CA, Mascola JR, Sodroski JG, Kwong PD. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci U S A 2012, 109:5663-5668. 10.1073/pnas.1112391109, 3326499, 22451932.
31. Liu L, Cimbro R, Lusso P, Berger EA. Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer. Proc Natl Acad Sci U S A 2011, 108:20148-20153. 10.1073/pnas.1104840108, 3250183, 22128330.
32. Rusert P, Krarup A, Magnus C, Brandenberg OF, Weber J, Ehlert AK, Regoes RR, Gunthard HF, Trkola A. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J Exp Med 2011, 208:1419-1433. 10.1084/jem.20110196, 3135368, 21646396.
33. Li Y, O'Dell S, Wilson R, Wu X, Schmidt SD, Hogerkorp CM, Louder MK, Longo NS, Poulsen C, Guenaga J, Chakrabarti BK, Doria-Rose N, Roederer M, Connors M, Mascola JR, Wyatt RT. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins. J Virol 2012, 86:11231-11241. 10.1128/JVI.01543-12, 3457177, 22875963.
34. Pancera M, Wyatt R. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoprotelins by potently neutralizing ligands requires efficient precursor cleavage. Virology 2005, 332:145-156. 10.1016/j.virol.2004.10.042, 15661147.
35. Chakrabarti BK, Pancera M, Phogat S, O'Dell S, McKee K, Guenaga J, Robinson J, Mascola J, Wyatt RT. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies. AIDS Res Hum Retroviruses 2011, 27:877-887. 10.1089/aid.2010.0281, 3159124, 21158699.
36. Klasse PJ, McKeating JA, Schutten M, Reitz MS, Robert-Guroff M. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(→Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site. Virology 1993, 196:332-337. 10.1006/viro.1993.1484, 8356803.
37. Thali M, Charles M, Furman C, Cavacini L, Posner M, Robinson J, Sodroski J. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change. J Virol 1994, 68:674-680. 236502, 7507184.
38. Klasse J, Pipkorn R, Blomberg J, Han KH, Hilton B, Ferretti JA. Three-dimensional structure and antigenicity of transmembrane-protein peptides of the human immunodeficiency virus type 1. Effects of a neutralization-escape substitution. FEBS Lett 1993, 323:68-72. 10.1016/0014-5793(93)81450-E, 8495750.
39. Blish CA, Nguyen MA, Overbaugh J. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med 2008, 5:e9. 10.1371/journal.pmed.0050009, 2174964, 18177204.
40. O'Rourke SM, Schweighardt B, Scott WG, Wrin T, Fonseca DP, Sinangil F, Berman PW. Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies. J Virol 2009, 83:7728-7738. 10.1128/JVI.00688-09, 2708639, 19474108.
41. Shen X, Dennison SM, Liu P, Gao F, Jaeger F, Montefiori DC, Verkoczy L, Haynes BF, Alam SM, Tomaras GD. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. Proc Natl Acad Sci U S A 2010, 107:5972-5977. 10.1073/pnas.0912381107, 2851912, 20231447.
42. Back NK, Smit L, Schutten M, Nara PL, Tersmette M, Goudsmit J. Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. J Virol 1993, 67:6897-6902. 238140, 8411395.
43. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Koff WC, Wilson IA, Burton DR, Poignard P. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470. 10.1038/nature10373, 3393110, 21849977.
44. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289. 10.1126/science.1178746, 3335270, 19729618.
45. Hoffenberg S, Powell R, Carpov A, Wagner D, Wilson A, Kosakovsky Pond S, Lindsay R, Arendt H, Destefano J, Phogat S, Poignard P, Fling SP, Simek M, Labranche C, Montefiori D, Wrin T, Phung P, Burton D, Koff W, King CR, Parks CL, Caulfield MJ. Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes. J Virol 2013, 87:5372-5383. 10.1128/JVI.02827-12, 3648150, 23468492.
46. Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, de la Pena AT, Cupo A, Julien JP, Van Gils M, Lee PS, Peng W, Paulson JC, Poignard P, Burton DR, Moore JP, Sanders RW, Wilson IA, Ward AB. Structural Delineation of a Quaternary, Cleavage-Dependent Epitope at the gp41-gp120 Interface on Intact HIV-1 Env Trimers. Immunity 2014, doi:10.1016/j.immuni.2014.04.008. [Epub ahead of print].
47. Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, Ramirez A, Derking R, Van Gils MJ, Liang CH, McBride R, Von Bredow B, Shivatare SS, Wu CY, Chan-Hui PY, Liu Y, Feizi T, Zwick MB, Koff WC, Seaman MS, Swiderek K, Moore JP, Evans D, Paulson JC, Wong CH, Ward AB, Wilson IA, Sanders RW, Poignard P, Burton DR. Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers. Immunity 2014, doi:10.1016/j.immuni.2014.04.009. [Epub ahead of print].
48. Klein JS, Bjorkman PJ. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog 2010, 6:e1000908. 10.1371/journal.ppat.1000908, 2877745, 20523901.
49. Klein JS, Gnanapragasam PN, Galimidi RP, Foglesong CP, West AP, Bjorkman PJ. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc Natl Acad Sci U S A 2009, 106:7385-7390. 10.1073/pnas.0811427106, 2678646, 19372381.
50. Klasse PJ. Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. Virology 2007, 369:245-262. 10.1016/j.virol.2007.06.044, 2317823, 17825343.
51. Klasse PJ, Moore JP. Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. J Virol 1996, 70:3668-3677. 190242, 8648701.
52. Magnus C, Regoes RR. Estimating the stoichiometry of HIV neutralization. PLoS Comput Biol 2010, 6:e1000713. 10.1371/journal.pcbi.1000713, 2841622, 20333245.
53. Magnus C, Regoes RR. Restricted occupancy models for neutralization of HIV virions and populations. J Theor Biol 2011, 283:192-202. 10.1016/j.jtbi.2011.06.004, 21683711.
54. Yuste E, Johnson W, Pavlakis GN, Desrosiers RC. Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus. J Virol 2005, 79:12455-12463. 10.1128/JVI.79.19.12455-12463.2005, 1211544, 16160173.
55. Zhu P, Liu J, Bess J, Chertova E, Lifson JD, Grise H, Ofek GA, Taylor KA, Roux KH. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006, 441:847-852. 10.1038/nature04817, 16728975.
56. Sok D, Laserson U, Laserson J, Liu Y, Vigneault F, Julien JP, Briney B, Ramos A, Saye KF, Le K, Mahan A, Wang S, Kardar M, Yaari G, Walker LM, Simen BB, St John EP, Chan-Hui PY, Swiderek K, Kleinstein SH, Alter G, Seaman MS, Chakraborty AK, Koller D, Wilson IA, Church GM, Burton DR, Poignard P. The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog 2013, 9:e1003754. 10.1371/journal.ppat.1003754, 3836729, 24278016.
57. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003, 300:2065-2071. 10.1126/science.1083182, 12829775.
58. Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, Liu Y, Marozsan A, Cupo A, Klasse PJ, Hoffenberg S, Caulfield M, King CR, Hua Y, Le KM, Khayat R, Deller MC, Clayton T, Tien H, Feizi T, Sanders RW, Paulson JC, Moore JP, Stanfield RL, Burton DR, Ward AB, Wilson IA. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol 2013, 20:796-803. 10.1038/nsmb.2594, 3823233, 23708606.
59. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329:811-817. 10.1126/science.1192819, 2981354, 20616231.
60. Crespillo S, Casares S, Mateo PL, Conejero-Lara F. Thermodynamic analysis of the binding of 2 F5 (Fab and immunoglobulin G forms) to its gp41 epitope reveals a strong influence of the immunoglobulin Fc region on affinity. J Biol Chem 2014, 289:594-599. 10.1074/jbc.C113.524439, 24302742.
61. Honnen WJ, Krachmarov C, Kayman SC, Gorny MK, Zolla-Pazner S, Pinter A. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence. J Virol 2007, 81:1424-1432. 10.1128/JVI.02054-06, 1797533, 17121806.
62. Burton DR, Saphire EO, Parren PW. A model for neutralization of viruses based on antibody coating of the virion surface. Curr Top Microbiol Immunol 2001, 260:109-143.
63. Klasse PJ, Sattentau QJ. Mechanisms of virus neutralization by antibody. Curr Top Microbiol Immunol 2001, 260:87-108.
64. Klasse PJ, Sattentau QJ. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol 2002, 83:2091-2108.
65. Burnet FM, Keogh EV, Lush D. The immunological reactions of the filterable viruses. Austral J Exp Biol and Med Science 1937, 15:227-368.
66. Vos Q, Klasen EA, Haaijman JJ. The effect of divalent and univalent binding on antibody titration curves in solid-phase ELISA. J Immunol Methods 1987, 103:47-54. 10.1016/0022-1759(87)90240-7, 2443578.
67. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai KF, O'Dell S, Patel N, Shahzad-ul-Hussan S, Yang YP, Zhang BS, Zhou TQ, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Do Kwon Y, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang LX, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD, et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480:336-U386. 10.1038/nature10696, 3406929, 22113616.
68. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, Poignard P, Burton DR, Pereyra F, Ho DD, Walker BD, Seaman MS, Bjorkman PJ, Chait BT, Nussenzweig MC. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 333:1633-1637. 10.1126/science.1207227, 3351836, 21764753.
69. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861. 10.1126/science.1187659, 2965066, 20616233.
70. Zeder-Lutz G, Hoebeke J, Van Regenmortel MH. Differential recognition of epitopes present on monomeric and oligomeric forms of gp160 glycoprotein of human immunodeficiency virus type 1 by human monoclonal antibodies. Eur J Biochem 2001, 268:2856-2866. 10.1046/j.1432-1327.2001.02167.x, 11358501.
71. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012, 30:423-433. 10.1038/nbt.2197, 3512202, 22565972.
72. Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, Pancera M, Zhou T, Incesu RB, Fu BZ, Gnanapragasam PN, Oliveira TY, Seaman MS, Kwong PD, Bjorkman PJ, Nussenzweig MC. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 2013, 153:126-138. 10.1016/j.cell.2013.03.018, 3792590, 23540694.
73. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC. Antibodies in HIV-1 vaccine development and therapy. Science 2013, 341:1199-1204. 10.1126/science.1241144, 3970325, 24031012.
74. Foote J, Milstein C. Kinetic maturation of an immune response. Nature 1991, 352:530-532. 10.1038/352530a0, 1907716.
75. Medina-Ramirez M, Sanders RW, Klasse PJ. Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development?. Expert Rev Vaccines 2014, 13:1-4. 10.1586/14760584.2014.864564, 24308582.
76. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009, 5:e1000433. 10.1371/journal.ppat.1000433, 2674935, 19436712.
77. Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, Piaskowski SM, Bergman Z, Watkins DI, Poignard P, Burton DR. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A 2012, 109:18921-18925. 10.1073/pnas.1214785109, 3503218, 23100539.
78. Platt EJ, Gomes MM, Kabat D. Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry. Proc Natl Acad Sci U S A 2012, 109:7829-7834. 10.1073/pnas.1109728109, 3356642, 22547820.
79. Ruprecht CR, Krarup A, Reynell L, Mann AM, Brandenberg OF, Berlinger L, Abela IA, Regoes RR, Gunthard HF, Rusert P, Trkola A. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J Exp Med 2011, 208:439-454. 10.1084/jem.20101907, 3058584, 21357743.
80. Ugolini S, Mondor I, Parren PW, Burton DR, Tilley SA, Klasse PJ, Sattentau QJ. Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. J Exp Med 1997, 186:1287-1298. 10.1084/jem.186.8.1287, 2199094, 9334368.
81. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekhar K, Gupta S, Nkolola JP, Seaman MS, Smith KM, Borducchi EN, Cabral C, Smith JY, Blackmore S, Sanisetty S, Perry JR, Beck M, Lewis MG, Rinaldi W, Chakraborty AK, Poignard P, Nussenzweig MC, Burton DR. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013, 503:224-228. 4017780, 24172905.
82. Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, Buckler-White A, Seaman M, Piatak M, Lifson JD, Dimitrov DS, Nussenzweig MC, Martin MA. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013, 503:277-280.
83. Weiss RA. Immunotherapy for HIV Infection. N Engl J Med 2014, 370:379-380. 10.1056/NEJMcibr1314577, 24450898.
84. Ketas TJ, Holuigue S, Matthews K, Moore JP, Klasse PJ. Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. Virology 2012, 422:22-36. 10.1016/j.virol.2011.09.019, 3229656, 22018634.
85. Wu X, Parast AB, Richardson BA, Nduati R, John-Stewart G, Mbori-Ngacha D, Rainwater SM, Overbaugh J. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol 2006, 80:835-844. 10.1128/JVI.80.2.835-844.2006, 1346878, 16378985.
86. Khayat R, Lee JH, Julien JP, Cupo A, Klasse PJ, Sanders RW, Moore JP, Wilson IA, Ward AB. Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. J Virol 2013, 87:9865-9872. 10.1128/JVI.01222-13, 3754114, 23824817.
87. Finzi A, Pacheco B, Zeng X, Kwon YD, Kwong PD, Sodroski J. Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. J Virol Methods 2010, 168:155-161. 10.1016/j.jviromet.2010.05.008, 2910153, 20471426.
88. Falkowska E, Ramos A, Feng Y, Zhou T, Moquin S, Walker LM, Wu X, Seaman MS, Wrin T, Kwong PD, Wyatt RT, Mascola JR, Poignard P, Burton DR. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J Virol 2012, 86:4394-4403. 10.1128/JVI.06973-11, 3318667, 22345481.
89. Moore JP, Cao Y, Conley AJ, Wyatt R, Robinson J, Gorny MK, Zolla-Pazner S, Ho DD, Koup RA. Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays. J Acquir Immune Defic Syndr 1994, 7:332-339.
90. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, Lammachia M, Garratty E, Stiehm ER, Bryson YJ, Cao Y, Moore JP, Ho DD, Barbas CF. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1027. 10.1126/science.7973652, 7973652.
91. Pantophlet R, Ollmann Saphire E, Poignard P, Parren PW, Wilson IA, Burton DR. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol 2003, 77:642-658. 10.1128/JVI.77.1.642-658.2003, 140633, 12477867.
92. Cavacini LA, Emes CL, Wisnewski AV, Power J, Lewis G, Montefiori D, Posner MR. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. AIDS Res Hum Retroviruses 1998, 14:1271-1280. 10.1089/aid.1998.14.1271, 9764911.
93. Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, Poignard P, Burton DR, Wilson IA. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A 2010, 107:11483-11488. 10.1073/pnas.1004600107, 2895122, 20534513.